SG11202000054RA - Bispecific anti pd1-anti tim3 antibodies - Google Patents
Bispecific anti pd1-anti tim3 antibodiesInfo
- Publication number
- SG11202000054RA SG11202000054RA SG11202000054RA SG11202000054RA SG11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA SG 11202000054R A SG11202000054R A SG 11202000054RA
- Authority
- SG
- Singapore
- Prior art keywords
- bispecific
- tim3 antibodies
- antibodies
- bispecific anti
- tim3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17180061 | 2017-07-06 | ||
PCT/NL2018/050450 WO2019009727A1 (en) | 2017-07-06 | 2018-07-06 | ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000054RA true SG11202000054RA (en) | 2020-02-27 |
Family
ID=59366222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000054RA SG11202000054RA (en) | 2017-07-06 | 2018-07-06 | Bispecific anti pd1-anti tim3 antibodies |
Country Status (15)
Country | Link |
---|---|
US (2) | US11753470B2 (de) |
EP (1) | EP3649155A1 (de) |
JP (1) | JP7422655B2 (de) |
KR (1) | KR20200042467A (de) |
CN (1) | CN111094348A (de) |
AU (1) | AU2018297058B2 (de) |
BR (1) | BR112020000227A2 (de) |
CA (1) | CA3068932A1 (de) |
EA (1) | EA202090004A1 (de) |
IL (1) | IL271832A (de) |
MX (1) | MX2020000055A (de) |
PH (1) | PH12020550013A1 (de) |
SG (1) | SG11202000054RA (de) |
TW (1) | TW201920657A (de) |
WO (1) | WO2019009727A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL271833B1 (en) * | 2017-07-06 | 2024-05-01 | Merus Nv | Antibodies that regulate biological activity expressed by a cell |
TW202340257A (zh) * | 2018-02-09 | 2023-10-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
TW202003569A (zh) * | 2018-03-30 | 2020-01-16 | 荷蘭商美勒斯公司 | 多價抗體 |
US20220213193A1 (en) * | 2019-05-06 | 2022-07-07 | Brown University | Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells |
CN114702587A (zh) | 2019-05-09 | 2022-07-05 | 美勒斯公司 | 用于使蛋白质多聚化的变体结构域及其分离 |
CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
WO2023089083A1 (en) * | 2021-11-19 | 2023-05-25 | Merus N.V. | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
PL2288715T3 (pl) | 2008-04-11 | 2015-03-31 | Merrimack Pharmaceuticals Inc | Łączniki będące albuminą surowicy ludzkiej i ich koniugaty |
KR102261586B1 (ko) | 2008-06-27 | 2021-06-08 | 메뤼스 엔.페. | 항체 생산 비-인간 포유동물 |
US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
CN114163530A (zh) | 2012-04-20 | 2022-03-11 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
PL2900694T3 (pl) | 2012-09-27 | 2018-12-31 | Merus N.V. | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
RU2729371C1 (ru) * | 2015-10-02 | 2020-08-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические к pd1 и tim3 |
WO2017055399A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
CN115925944A (zh) * | 2015-10-23 | 2023-04-07 | 美勒斯公司 | 抑制癌症生长的结合分子 |
BR112018008891A8 (pt) * | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
-
2018
- 2018-07-06 TW TW107123602A patent/TW201920657A/zh unknown
- 2018-07-06 CA CA3068932A patent/CA3068932A1/en active Pending
- 2018-07-06 SG SG11202000054RA patent/SG11202000054RA/en unknown
- 2018-07-06 BR BR112020000227-5A patent/BR112020000227A2/pt unknown
- 2018-07-06 EP EP18749180.8A patent/EP3649155A1/de active Pending
- 2018-07-06 CN CN201880055838.7A patent/CN111094348A/zh active Pending
- 2018-07-06 US US16/628,937 patent/US11753470B2/en active Active
- 2018-07-06 MX MX2020000055A patent/MX2020000055A/es unknown
- 2018-07-06 AU AU2018297058A patent/AU2018297058B2/en active Active
- 2018-07-06 WO PCT/NL2018/050450 patent/WO2019009727A1/en unknown
- 2018-07-06 JP JP2020500087A patent/JP7422655B2/ja active Active
- 2018-07-06 KR KR1020207003656A patent/KR20200042467A/ko not_active Application Discontinuation
- 2018-07-06 EA EA202090004A patent/EA202090004A1/ru unknown
-
2020
- 2020-01-05 IL IL271832A patent/IL271832A/en unknown
- 2020-01-06 PH PH12020550013A patent/PH12020550013A1/en unknown
-
2023
- 2023-07-26 US US18/359,660 patent/US20230357407A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3649155A1 (de) | 2020-05-13 |
PH12020550013A1 (en) | 2020-10-12 |
JP7422655B2 (ja) | 2024-01-26 |
JP2020532281A (ja) | 2020-11-12 |
WO2019009727A1 (en) | 2019-01-10 |
CA3068932A1 (en) | 2019-01-10 |
BR112020000227A2 (pt) | 2020-09-29 |
CN111094348A (zh) | 2020-05-01 |
US20200216539A1 (en) | 2020-07-09 |
WO2019009727A8 (en) | 2020-01-30 |
US20230357407A1 (en) | 2023-11-09 |
IL271832A (en) | 2020-02-27 |
EA202090004A1 (ru) | 2020-06-18 |
US11753470B2 (en) | 2023-09-12 |
AU2018297058A1 (en) | 2020-01-30 |
AU2018297058B2 (en) | 2021-04-29 |
TW201920657A (zh) | 2019-06-01 |
KR20200042467A (ko) | 2020-04-23 |
MX2020000055A (es) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256365A1 (zh) | 對pd1和tim3特異性的雙特異性抗體 | |
IL279235A (en) | DLL3-CD3 bispecific antibodies | |
PL3519437T3 (pl) | Przeciwciała dwuswoiste przeciwko p95HER2 | |
ZA201801673B (en) | Optimized anti¿cd3 bispecific antibodies and uses thereof | |
ZA201908549B (en) | Checkpoint inhibitor bispecific antibodies | |
IL271832A (en) | Bispecific antibodies against PD1 and against TIM3 | |
EP3487888A4 (de) | Bispezifischer anti-her2-antikörper | |
PL3130606T3 (pl) | Przeciwciała dwuswoiste aktywujące układ odpornościowy | |
GB201710838D0 (en) | Bispecific antibodies | |
EP3507307A4 (de) | Bispezifische antikörper | |
IL262776A (en) | Human anti-il-1r3 antibodies | |
ZA202004908B (en) | Bispecific antibody | |
EP3377112A4 (de) | Chemisch blockierte bispezifische antikörper | |
IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
IL282355A (en) | Bispecific antibodies directed to exosomes | |
EP3693013A4 (de) | Bispezifischer antikörper | |
SG11201610594WA (en) | Anti-il4-il 13 bispecific antibodies | |
IL274676A (en) | The bispecific antigen binding composition | |
EP3728311A4 (de) | Bispezifische hiv-1-neutralisierende antikörper | |
IL272676B (en) | Bispecific antibodies against il-4 and il-13 | |
GB201511196D0 (en) | Monoclonal antibodies |